Intravenous bolus topotecan in patients with myelodysplastic syndrome

K. Seiter; D. Liu; E. J. Feldman; A. D. Siddiqui; A. Hoang; P. Baskind; R. Kancherla; T. Ahmed

doi:10.3109/10428190109097715

Intravenous bolus topotecan in patients with myelodysplastic syndrome

K. Seiter, D. Liu, E. J. Feldman, A. D. Siddiqui, A. Hoang, P. Baskind, R. Kancherla, T. Ahmed

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m²/d, 2.0 mg/m²/d or 2.5 mg/m²/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.

Original language	English (US)
Pages (from-to)	963-968
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	42
Issue number	5
DOIs	https://doi.org/10.3109/10428190109097715
State	Published - 2001
Externally published	Yes

Keywords

Bolus
MDS
Myelodysplastic syndrome
Topotecan

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428190109097715

Cite this

@article{1d6892b480bc49cb81ab2299becea993,

title = "Intravenous bolus topotecan in patients with myelodysplastic syndrome",

abstract = "We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.",

keywords = "Bolus, MDS, Myelodysplastic syndrome, Topotecan",

author = "K. Seiter and D. Liu and Feldman, {E. J.} and Siddiqui, {A. D.} and A. Hoang and P. Baskind and R. Kancherla and T. Ahmed",

year = "2001",

doi = "10.3109/10428190109097715",

language = "English (US)",

volume = "42",

pages = "963--968",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Intravenous bolus topotecan in patients with myelodysplastic syndrome

AU - Seiter, K.

AU - Liu, D.

AU - Feldman, E. J.

AU - Siddiqui, A. D.

AU - Hoang, A.

AU - Baskind, P.

AU - Kancherla, R.

AU - Ahmed, T.

PY - 2001

Y1 - 2001

N2 - We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.

AB - We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.

KW - Bolus

KW - MDS

KW - Myelodysplastic syndrome

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0034846008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034846008&partnerID=8YFLogxK

U2 - 10.3109/10428190109097715

DO - 10.3109/10428190109097715

M3 - Article

C2 - 11697651

AN - SCOPUS:0034846008

SN - 1042-8194

VL - 42

SP - 963

EP - 968

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -

Intravenous bolus topotecan in patients with myelodysplastic syndrome

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this